Navigation Links
Data From REMEDEE Trial Featuring OrbusNeich's Combo™ Dual Therapy Stent to be Presented in Late Breaking Clinical Trials and First Report Investigations Session at TCT 2011
Date:11/1/2011

out OrbusNeich

OrbusNeich is a global company that designs, develops, manufactures and markets innovative medical devices for the treatment of vascular diseases. Current products are the world's first pro-healing stent, the Genous Stent, as well as other stents and balloons marketed under the names of Azule™, R stent, Scoreflex™, Sapphire™, Sapphire II and Sapphire NC. Development stage products include the Combo Dual Therapy Stent, the only dual therapy stent to both accelerate endothelial coverage and control neo-intimal proliferation through the combination of the Genous pro-healing technology with an abluminal sirolimus drug elution. OrbusNeich is headquartered in Hong Kong and has operations in Shenzhen, China; Fort Lauderdale, Fla.; Hoevelaken, The Netherlands; and Tokyo, Japan. OrbusNeich supplies medical devices to interventional cardiologists in more than 60 countries. For more information, visit www.OrbusNeich.com.

Follow OrbusNeich on Twitter at www.twitter.com/OrbusNeich, and learn more about the company and the Genous technology on OrbusNeich's YouTube Channel: http://www.youtube.com/user/OrbusNeichMedical.

Editor's Notes: OrbusNeich will display the Combo Dual Therapy Stent, the Genous Stent and other products at booth No. 1429 at TCT 2011. Product images are available on request.


'/>"/>
SOURCE OrbusNeich
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Conatus Pharmaceuticals Terminates Phase 2 Clinical Trial of CTS-1027
2. CTRI Confirms Leading Indian CRO Supports Majority of Hemophilia Trials in India
3. Industrial Biotechnology China News 1109 - Annual Subscription
4. Cardiac Dimensions Announces First Patient Treated in TITAN II Clinical Trial
5. Californias Industrial Biotechnology Workforce: Creating Jobs and Leading Innovation
6. Defense Witness In Second Hepatitis C Trial In Nevada, Dr. Arthur Reingold, Testimony on Plausible Cause for Contamination Impeached
7. Halozyme Begins Clinical Trial with HTI-501 in Women with Edematous Fibrosclerotic Panniculopathy
8. Circassias Hay Fever Treatment Improves Patients Allergy Symptoms in Phase II Clinical Trial
9. SanBio Announces Site Opening of Phase 1/2a Clinical Trial of Novel Cell Therapy in Stable Stroke Patients at University of Pittsburgh Medical Center
10. Roka Bioscience Initiates External Trial for AOAC Certification
11. Aperion Biologics Reaches Midpoint of Enrollment in Z-Lig™ Anterior Cruciate Ligament Reconstruction Medical Device Performance Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... NY (PRWEB) June 18, 2013 In ... and sustainability, the Consulate General of Switzerland in New ... boat, Switzerland’s MS Tûranor PlanetSolar , to Manhattan. ... of its DeepWater Expedition 2013 tour with scientists on ... by Capitain Gérard d’Aboville, runs exclusively on energy from ...
(Date:6/18/2013)... Demanding industrial and environmental conditions are no ... and Glass Ball Lenses, now available in an extensive ... , of Philadelphia , PA. , Optical Ball Lenses ... beams without the need for direct physical contact. That’s ... mohs) make it the ideal choice for fiber-optic applications ...
(Date:6/18/2013)... AZ (PRWEB) June 18, 2013 Nasseo, ... 2013 Innovation Challenge Winner out of hundreds of applicants ... its spring Arizona Innovation Challenge . The Arizona ... country for a technology commercialization challenge, granting a financial ... most promising technology ventures. Nasseo’s state of the art ...
(Date:6/18/2013)... ATLANTA , June 18, 2013  regulated information ... Jeff Klauk today announced the launch of ... their loved ones. The Pledge ... take a stand and make a personal commitment to ... with their health care team and additional partial-onset seizure ...
Breaking Biology Technology:Switzerland’s MS Tûranor PlanetSolar, the World’s Largest Solar Boat, Arrives in New York City 2Switzerland’s MS Tûranor PlanetSolar, the World’s Largest Solar Boat, Arrives in New York City 3Switzerland’s MS Tûranor PlanetSolar, the World’s Largest Solar Boat, Arrives in New York City 4Swiss Jewel Introduces the Crown Jewels of Fiber-Optic Connectors 2Nasseo Named 2013 Innovation Challenge Winner by Arizona Commerce Authority 2Professional Golfer Jeff Klauk Tees Off New Pledge Campaign for People Living with Epilepsy 2Professional Golfer Jeff Klauk Tees Off New Pledge Campaign for People Living with Epilepsy 3Professional Golfer Jeff Klauk Tees Off New Pledge Campaign for People Living with Epilepsy 4Professional Golfer Jeff Klauk Tees Off New Pledge Campaign for People Living with Epilepsy 5Professional Golfer Jeff Klauk Tees Off New Pledge Campaign for People Living with Epilepsy 6
... Calif., Jan. 12 WaferGen Biosystems,Inc. (OTC ... state-of-the-art gene,expression, genotyping, cell biology and stem ... have successfully demonstrated the,performance of the company,s ... of the platform,s ongoing alpha testing program. ...
... -- Simcere Pharmaceutical Group,(NYSE: SCR ), ... and manufacturer of the patented anti-cancer biotech product,Endu ... preliminary revenue,and earnings for the full year of ... preliminary data for the fourth quarter, Simcere expects ...
... PHOENIX, Jan. 9 Houlihan Smith & Co., ... non-control equity investment,into Sottera, Inc. d/b/a NJOY, as ... Chairman of Houlihan Smith & Company, Inc. ... Reginald McGaugh.,Terms were not disclosed. , ...
Cached Biology Technology:WaferGen's SmartChip(TM) System Performance Successfully Demonstrated in Initial Phase of Alpha Testing Program 2WaferGen's SmartChip(TM) System Performance Successfully Demonstrated in Initial Phase of Alpha Testing Program 3WaferGen's SmartChip(TM) System Performance Successfully Demonstrated in Initial Phase of Alpha Testing Program 4WaferGen's SmartChip(TM) System Performance Successfully Demonstrated in Initial Phase of Alpha Testing Program 5Simcere Pharmaceutical Group Announces Preliminary Full Year Revenue and Earnings 2Houlihan Smith Arranges Non-Control Equity Investment Into Sottera, Inc., dba NJOY, by Miri Pharma, Inc. 2
(Date:6/19/2013)... In fall 2012, the European Medicines Agency (EMA) ... the first ever gene therapy for clinical use ... company, had developed AAV-LPL S447X for the treatment ... lipase deficiency (LPLD) which affects approximately one or ... causes severe, life-threatening inflammations of the pancreas. Afflicted ...
(Date:6/18/2013)...  Paris Air Show – Marvin Test ... a leading provider of innovative test solutions for ... solutions this week at the Paris Air ... including increasingly complex armament systems with longer lifecycles, ... test solutions that address legacy system obsolescence. Marvin ...
(Date:6/18/2013)... Energy Department,s National Renewable Energy Laboratory (NREL), and ... paper describing a novel cellulose-degrading enzyme from a ... known as the gribble. , Gribbles are ... ability to produce their own enzymes instead of ... they eat. New biomass-degrading enzymes from novel sources ...
Breaking Biology News(10 mins):No danger of cancer through gene therapy virus 2Marvin Test Solutions Demonstrates Next-Generation Armament Test Solutions at Paris Air Show 2Marvin Test Solutions Demonstrates Next-Generation Armament Test Solutions at Paris Air Show 3Novel enzyme from tiny gribble could prove a boon for biofuels research 2
... Austin-based startup cofounded by Mauro Ferrari, Ph.D., of The ... to improve the effectiveness of anti-cancer agents and other ... through the Texas Emerging Technology Fund (ETF). NMS ... awards, which were announced by Texas Gov. Rick Perry ...
... -- The body,s immune system hates strangers. When its ... This is the problem when people with type ... cells from a donor pancreas produce robust amounts of ... insulin therapy. However, the immune system tries to kill ...
... of birth, mouse ovaries are essentially a bag full ... This key time in ovarian development establishes the population ... cohort of follicles. If follicles fail to form, the ... for follicular development. Several factors key to follicular formation ...
Cached Biology News:Texas invests record $3.5 million in startup cofounded by UT's Mauro Ferrari 2New technique eliminates toxic drugs in islet transplant in diabetic mice 2December 2008 highlights from Biology of Reproduction 2